Theolytics Ltd

Active11001290 Private limited company
Incorporated
6 October 2017 (9 years)
Industry
Research and experimental development on biotechnology (72110)
Accounts type
Small
Region
South East
Address
4610 Kingsgate Cascade Way
Arc Oxford
Oxford
OX4 2SU

Filing status

Accounts due
30 September 2027
Last accounts
31 December 2025
Conf. stmt due
19 October 2027
Last conf. stmt
5 October 2026

Charges

Total
3
Outstanding
1
Part satisfied
0
Satisfied
2

Officers 9 active

Officer details are public data from the Companies House register.

Director · Appointed 9 July 2026
British
Born November 1989
Johnson, Emma
Director · Appointed 4 June 2026
British
Born June 1996 (30)
Director · Appointed 24 December 2024
British
Born October 1992 (34)
Apelian, David, Dr
Director · Appointed 4 November 2024
American
Born April 1965 (61)
Kordel, Johan
Director · Appointed 27 September 2024
Swedish
Born April 1962 (64)
Director · Appointed 30 November 2023
British
Born July 1967 (59)
Grey, Mike George
Director · Appointed 30 November 2023
American
Born December 1952 (73)
Director · Appointed 22 December 2020
Japanese
Born May 1965 (61)
Duffy, Margaret, Dr
Director · Appointed 19 December 2017
Irish
Born October 1986 (40)
Officer history (10 former)
9 July 2026
Appointed Dixon-Clegg, Nicholas George as Director
9 July 2026
Resigned Wallace, Wallace Lucy Elizabeth as Director
4 June 2026
Appointed Johnson, Emma as Director
4 June 2026
Resigned Yerushalmi, Noga as Director
24 December 2024
Appointed Edwardes Jones, Lucy Charlotte as Director
2 December 2024
Resigned Reinhardt, Carsten Alexander Johannes, Dr as Director
2 December 2024
Appointed Wallace, Wallace Lucy Elizabeth as Director
4 November 2024
Appointed Apelian, David, Dr as Director
27 September 2024
Resigned Liechtenstein, Therese Maria as Director
27 September 2024
Appointed Yerushalmi, Noga as Director
27 September 2024
Appointed Kordel, Johan as Director
27 September 2024
Resigned Tan, Thomas, Dr as Director
12 July 2024
Resigned Casebourne Stock, Charlotte as Director
31 May 2024
Resigned Oakley, Andrew John as Director
4 April 2024
Appointed Tan, Thomas, Dr as Director
27 December 2023
Appointed Oakley, Andrew John as Director
30 November 2023
Appointed Grey, Mike George as Director
30 November 2023
Appointed Finan, Peter Michael, Dr as Director
30 November 2023
Resigned Powell, Kenneth Leslie, Dr as Director
30 November 2023
Resigned Steinhagen, Henning as Director
1 July 2021
Appointed Liechtenstein, Therese Maria as Director
22 December 2020
Appointed Asanuma, Sakae as Director
22 December 2020
Appointed Steinhagen, Henning as Director
14 August 2020
Appointed Reinhardt, Carsten Alexander Johannes, Dr as Director
14 August 2020
Resigned Mclean, Andrew James, Dr as Director
1 January 2019
Appointed Powell, Kenneth Leslie, Dr as Director
19 December 2017
Appointed Mclean, Andrew James, Dr as Director
19 December 2017
Appointed Duffy, Margaret, Dr as Director
6 October 2017
Appointed Casebourne Stock, Charlotte as Director

Ownership 0 active

People and entities with significant control, from the Companies House PSC register

The company has declared that it has no person with significant control.
Former controllers (2)
21 August 2023
Ceased Oxford Science Enterprises PLC — Owns 25–50% of shares
13 February 2018
Ceased Charlotte Casebourne Mills — Owns 75–100% of shares

Financials

Net Assets
£8,666,096
Cash
£7,678,945
Profit
(£8,638,843)
Employees
30
Debt Ratio
18%
Current Ratio
5.3x
Return on Equity
-100%

Trend

Net Assets
£0 £5.0M £10.0M 2020 2021 2022 2023 £182,740 £7,258,486 £3,198,505 £8,666,096
Balance sheet detail
20232022202120202019
Fixed Assets£507,485£465,775£391,963£187,732£210,971
Current Assets£10,052,079£8,650,589£7,349,632£1,548,502£1,319,045
Debtors£289,793
Cash£7,678,945£7,322,094£6,551,235£1,149,881£1,029,252
Creditors (< 1 year)£1,885,451£5,917,859£483,109£1,553,494£147,965
Net Current Assets£8,166,628£2,732,730£6,866,523(£4,992)£1,171,080
Net Assets£8,666,096£3,198,505£7,258,486£182,740
Shareholder Funds£8,666,096£3,198,505£7,258,486£182,740£1,382,051

What Theolytics say about themselves

“Our Adenovo™ platform and 100-million-variant library move us from discovery to impact. With THEO-260 as our lead programme, our world-class team is applying world-leading science to expand access to innovative therapies that promise lasting benefit.”

— from theolytics.com

Filings

Filing history not loaded yet. See it on Companies House

Other companies in this industry

By trade and location

New companies in Oxford →

Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →

← Back to companies Official record on Companies House ↗

Already have an account?

Create your account

Save searches and get the weekly email of new matches.

First name is required.
Last name is required.
Enter an email address like name@example.com.
Must be at least 8 characters. Password must be at least 8 characters.

Already have an account?